BP-294 Ste Civile Bioprojet.
BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine H3 agonist under development by Bioprojet and in phase II clinical trials as an antiasthmatic [219798]. In a study, R-alpha-methylhistamine was shown to inhibit the release of acetylcholine, in the presence of atropine (1 microM) and 0.5 Hz of electrical stimulation of the rat bilateral vagus nerve, in a dose-dependent manner. This inhibition was abolished by thioperamide [321838].
Novartis Preclinical Research, Asthma Building 386/1035, Postfach, CH-4002 Basel, Switzerland. john_r.fozard@pharma.novartis.com
J R
JR
Fozard
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001249:Asthma / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007097:Imines / Q000378:metabolism* / Q000494:pharmacology / Q000633:toxicity; D010636:Phenols / Q000378:metabolism* / Q000494:pharmacology / Q000633:toxicity; D013329:Structure-Activity Relationship
D018927:Anti-Asthmatic Agents; D015507:Drugs, Investigational; D007097:Imines; D010636:Phenols; C106714:BP 2-94